
Opthea (OPT) Stock Forecast & Price Target
Opthea (OPT) Analyst Ratings
Bulls say
Opthea Ltd is focused on advancing its novel biologic therapy, OPT-302, for eye diseases, specifically targeting key vascular growth factors, which positions it well within the medical technology and healthcare sector. The company aims to demonstrate substantial vision improvements in patients through its Phase 3 trials, with a notable previous performance indicating a +5.7 letter gain in visual acuity among a significant patient subgroup, which suggests a promising potential for commercial adoption by retinal specialists. Furthermore, the alignment of clinical efficacy with payer outlooks on vision improvement thresholds enhances the company’s likelihood of securing broad market coverage and strengthens the basis for a positive investment perspective.
Bears say
Opthea Ltd reported a significant net loss of $131.9 million, or $0.11 per share, for the first half of FY 2025, raising concerns about its financial sustainability. The company faces several risks, including the potential failure of its developmental candidate, OPT-302, to meet projected peak commercial revenue estimates, which could be impacted by market size, penetration rates, and pricing strategies. Additionally, Opthea's ability to secure necessary capital resources for ongoing operations and program development remains uncertain, further contributing to a negative outlook on its financial stability.
This aggregate rating is based on analysts' research of Opthea and is not a guaranteed prediction by Public.com or investment advice.
Opthea (OPT) Analyst Forecast & Price Prediction
Start investing in Opthea (OPT)
Order type
Buy in
Order amount
Est. shares
0 shares